Clinical trials in stroke intervention during the past year have yielded contrasting results. Endovascular therapies and procedures to reduce stroke risk caused by patent foramen ovale have failed to demonstrate superiority over standard medical treatments. By contrast, a trial of neuroprotection—traditionally thought to be ineffective in humans—offers hope.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Neuron-secreted NLGN3 ameliorates ischemic brain injury via activating Gαi1/3-Akt signaling
Cell Death & Disease Open Access 25 October 2023
-
Oxygen glucose deprivation/re-oxygenation-induced neuronal cell death is associated with Lnc-D63785 m6A methylation and miR-422a accumulation
Cell Death & Disease Open Access 30 September 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Broderick, J. P. et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N. Engl. J. Med. 368, 893–903 (2013).
Ciccone, A. et al. Endovascular treatment for acute ischemic stroke. N. Engl. J. Med. 368, 904–913 (2013).
Kidwell, C. S. et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N. Engl. J. Med. 368, 914–923 (2013).
Carroll, J. D. et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N. Engl. J. Med. 368, 1092–1100 (2013).
Meier, B. et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N. Engl. J. Med. 368, 1083–1091 (2013).
Hill, M. D. et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 11, 942–950 (2012).
Rha, J. H. & Saver, J. L. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 3, 967–973 (2007).
Cook, D. J., Teves, L. & Tymianski, M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 483, 213–217 (2012).
Furlan, A. J. et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N. Engl. J. Med. 366, 991–999 (2012).
O'Collins, V. E. et al. 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467–477 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. Tymianski is president of NoNO Inc., a biotechnology company founded to develop PSD95 inhibitors discovered in his research laboratory.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Tymianski, M. Disappointments and advances in acute stroke intervention. Nat Rev Neurol 10, 66–68 (2014). https://doi.org/10.1038/nrneurol.2013.271
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2013.271
This article is cited by
-
Neuron-secreted NLGN3 ameliorates ischemic brain injury via activating Gαi1/3-Akt signaling
Cell Death & Disease (2023)
-
Oxygen glucose deprivation/re-oxygenation-induced neuronal cell death is associated with Lnc-D63785 m6A methylation and miR-422a accumulation
Cell Death & Disease (2020)
-
Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review
Metabolic Brain Disease (2019)
-
Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginine–Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats
NeuroMolecular Medicine (2017)
-
Neuroprotective strategies for NMDAR-mediated excitotoxicity in Huntington’s Disease
Frontiers in Biology (2016)
